ULK1, a novel therapeutic target to delay drug tolerance to EGFR-TKIs in an EGFR-mutant non-small cell lung cancer model
{{output}}
Background: The presence of drug-tolerant persister (DTP) cells reduces the effectiveness of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in EGFR-mutated non-small cell lung cancer (NSCLC). Although a... ...
